Seok Jin Nam

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7694756/publications.pdf

Version: 2024-02-01

172457 3,834 201 29 citations h-index papers

g-index 213 213 213 6441 docs citations times ranked citing authors all docs

223800

46

#	Article	IF	CITATIONS
1	Effect of mind and body education on quality of life among young breast cancer patients: a randomized controlled trial. Supportive Care in Cancer, 2022, 30, 721-729.	2.2	3
2	Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients. Cancer Research and Treatment, 2022, 54, 827-833.	3.0	2
3	Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors. Cancer Research and Treatment, 2022, 54, 834-841.	3.0	9
4	Immediate breast reconstruction has no impact on the oncologic outcomes of patients treated with post-mastectomy radiation therapy: a comparative analysis based on propensity score matching. Breast Cancer Research and Treatment, 2022, 192, 101-112.	2.5	1
5	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Cancer Research and Treatment, 2022, , .	3.0	8
6	Histologic analysis according to HER2 gene status in HER2 2 + invasive breast cancer: a study of 280 cases comparing ASCO/CAP 2013 and 2018 guideline recommendations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 749-758.	2.8	2
7	Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer. Cancer Research, 2022, 82, P1-08-07-P1-08-07.	0.9	O
8	Abstract OT1-04-02: The NAUTILUS trial (No Axillary sUrgical Treatment In clinically Lymph node) Tj ETQq0 0 0 rg (NCT04303715). Cancer Research, 2022, 82, OT1-04-02-OT1-04-02.	gBT /Overlo 0.9	ock 10 Tf 50 4 0
9	Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. Cancer Research, 2022, 82, P3-13-08-P3-13-08.	0.9	O
10	Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society. Journal of Breast Cancer, 2022, 25, 94.	1.9	4
11	Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. European Journal of Surgical Oncology, 2021, 47, 232-239.	1.0	7
12	Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006). Journal of Breast Cancer, 2021, 24, 164.	1.9	2
13	Changes in Korean National Healthcare Insurance Policy and Breast Cancer Surgery Trend in Korea. Journal of Korean Medical Science, 2021, 36, e194.	2.5	2
14	Effect of Poloxamer-Based Thermo-Sensitive Sol-Gel Agent on Upper Limb Dysfunction after Axillary Lymph Node Dissection: A Double-Blind Randomized Clinical Trial. Journal of Breast Cancer, 2021, 24, 367.	1.9	3
15	Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2â^ Early Breast Cancer. Frontiers in Oncology, 2021, 11, 588728.	2.8	2
16	Abstract PS10-38: Real Would Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience., 2021,,.		0
17	The efficacy and safety of indocyanine green-hyaluronic acid mixture (LuminoMarkâ,,¢) for localization in patients with non-palpable breast lesions: a multi-center open-label parallel phase-2 clinical trial. BMC Surgery, 2021, 21, 134.	1.3	5
18	Celastrol attenuates the inflammatory response by inhibiting $L\hat{a}\in \hat{1}^2$ expression in triple $\hat{a}\in \hat{1}$ negative breast cancer cells. Oncology Reports, 2021, 45, .	2.6	17

#	Article	IF	Citations
19	Association between cancer stigma and job loss among cancer survivors. Psycho-Oncology, 2021, 30, 1347-1355.	2.3	19
20	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. Frontiers in Oncology, 2021, 11, 596364.	2.8	14
21	Entelon \hat{A}^{\otimes} (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells. Molecules, 2021, 26, 3644.	3.8	7
22	Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. Frontiers in Oncology, 2021, 11, 691277.	2.8	4
23	Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer. Breast Cancer Research and Treatment, 2021, 189, 747-757.	2.5	10
24	Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients. Scientific Reports, 2021, 11, 14747.	3.3	1
25	Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11. 608207.	2.8	1
26	Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 741120.	2.8	2
27	Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea. Breast Cancer Research and Treatment, 2021, 189, 653-663.	2.5	10
28	Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?. BMC Cancer, 2021, 21, 88.	2.6	8
29	Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. Journal of Breast Cancer, 2021, 24, 75.	1.9	19
30	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Cancers, 2021, 13, 5260.	3.7	11
31	Is Sentinel Lymph Node Biopsy for Breast Cancer with Cytology-Proven Axillary Metastasis Safe? A Prospective Single-Arm Study. Journal of Clinical Medicine, 2021, 10, 4754.	2.4	0
32	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology, 2020, 38, 434-443.	1.6	52
33	Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence. JAMA Surgery, 2020, 155, 1132.	4.3	27
34	Response of Triple-negative Breast Cancer Liver Metastasis to Oral Recombinant Methioninase in a Patient-derived Orthotopic Xenograft (PDOX) Model. In Vivo, 2020, 34, 3163-3169.	1.3	12
35	Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nature Communications, 2020, 11, 6175.	12.8	92
36	WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells. Cytokine, 2020, 135, 155213.	3.2	9

#	Article	IF	CITATIONS
37	Distribution of tumor subtypes in bilateral breast cancer: Comparison between synchronous and metachronous cancer. Asia-Pacific Journal of Clinical Oncology, 2020, , .	1.1	5
38	Oral Methioninase Inhibits Recurrence in a PDOX Mouse Model of Aggressive Triple-negative Breast Cancer. In Vivo, 2020, 34, 2281-2286.	1.3	12
39	Impact of Serum Lipid on Breast Cancer Recurrence. Journal of Clinical Medicine, 2020, 9, 2846.	2.4	23
40	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. Breast Cancer Research and Treatment, 2020, 184, 325-334.	2.5	18
41	Dietary Intake and Plasma Levels of Isoflavones Among Breast Cancer Survivors. Current Developments in Nutrition, 2020, 4, nzaa 061_118 .	0.3	0
42	A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model. Anticancer Research, 2020, 40, 2481-2485.	1.1	6
43	Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Research, 2020, 22, 54.	5.0	32
44	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. Molecular Cancer Research, 2020, 18, 1315-1325.	3.4	8
45	Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. Japanese Journal of Clinical Oncology, 2020, 50, 104-113.	1.3	2
46	Efficacy of health coaching and a webâ€based program on physical activity, weight, and distress management among cancer survivors: A multiâ€centered randomised controlled trial. Psycho-Oncology, 2020, 29, 1105-1114.	2.3	28
47	Aberrant Lymphatic Drainage in the Contralateral Axilla in Patients with Isolated Ipsilateral Breast Tumor Recurrence. Journal of Clinical Medicine, 2020, 9, 1192.	2.4	0
48	Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast. Journal of Pathology and Translational Medicine, 2020, 54, 95-102.	1.1	19
49	Surgical impact on anxiety of patients with breast cancer: 12-month follow-up prospective longitudinal study. Annals of Surgical Treatment and Research, 2020, 98, 215.	1.0	8
50	Is the intraoperative frozen section analysis of sentinel lymph nodes necessary in clinically negative node breast cancer?. Annals of Surgical Treatment and Research, 2020, 99, 251.	1.0	5
51	Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients. Journal of Breast Cancer, 2020, 23, 259.	1.9	3
52	TP53 upregulates αâ€'smooth muscle actin expression in tamoxifenâ€'resistant breast cancer cells. Oncology Reports, 2019, 41, 1075-1082.	2.6	7
53	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. Journal of Global Oncology, 2019, 5, 1-9.	0.5	13
54	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice, 2019, 17, 1.	1.5	13

#	Article	IF	CITATIONS
55	Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients. Nutrients, 2019, 11, 37.	4.1	46
56	Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2019, 176, 591-596.	2.5	25
57	Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean. Journal of Global Oncology, 2019, 5, 1-10.	0.5	9
58	Practical approaches to automated digital image analysis of Ki-67 labeling index in 997 breast carcinomas and causes of discordance with visual assessment. PLoS ONE, 2019, 14, e0212309.	2.5	18
59	Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer. Annals of Surgical Treatment and Research, 2019, 96, 169.	1.0	22
60	Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. Breast Cancer Research and Treatment, 2019, 175, 203-215.	2.5	13
61	Immune gene expression profiling reveals heterogeneity in luminal breast tumors. Breast Cancer Research, 2019, 21, 147.	5.0	43
62	Adherence to the American Cancer Society Guidelines for Cancer Survivors and Health-Related Quality of Life among Breast Cancer Survivors. Nutrients, 2019, 11, 2924.	4.1	13
63	Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Research and Treatment, 2019, 173, 385-395.	2.5	15
64	A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning. European Journal of Surgical Oncology, 2019, 45, 134-140.	1.0	17
65	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Research and Treatment, 2019, 173, 255-266.	2.5	96
66	Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?. Breast Cancer Research and Treatment, 2019, 173, 189-199.	2.5	27
67	EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer. Cellular Physiology and Biochemistry, 2019, 53, 805-819.	1.6	26
68	Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm. Journal of Breast Cancer, 2019, 22, 613.	1.9	18
69	Phase II randomized study of neoadjuvant metformin plus letrozole versus placebo plus letrozole for ER-positive postmenopausal breast cancer [METEOR Study] Journal of Clinical Oncology, 2019, 37, 576-576.	1.6	6
70	Berberine Suppresses Cell Motility Through Downregulation of TGF- \hat{l}^21 in Triple Negative Breast Cancer Cells. Cellular Physiology and Biochemistry, 2018, 45, 795-807.	1.6	47
71	A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors. BMC Cancer, 2018, 18, 45.	2.6	7
72	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. Clinical Breast Cancer, 2018, 18, e1165-e1172.	2.4	1

#	Article	IF	Citations
73	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer, 2018, 18, e1141-e1147.	2.4	24
74	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nature Communications, 2018 , 9 , 1725 .	12.8	122
75	Preoperative Axillary US in Early-Stage Breast Cancer: Potential to Prevent Unnecessary Axillary Lymph Node Dissection. Radiology, 2018, 288, 55-63.	7.3	37
76	Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane. Clinical Breast Cancer, 2018, 18, e49-e54.	2.4	18
77	Development and validation of the smart management strategy for health assessment tool-short form (SAT-SF) in cancer survivors. Quality of Life Research, 2018, 27, 347-354.	3.1	8
78	Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. Translational Oncology, 2018, 11, 18-23.	3.7	26
79	Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer. World Journal of Surgery, 2018, 42, 1384-1390.	1.6	9
80	BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. PLoS ONE, 2018, 13, e0207155.	2.5	12
81	Patterns of Axillary Lymph Node Metastasis in Breast Cancer: A Prospective Single-Center Study. Journal of Breast Cancer, 2018, 21, 447.	1.9	2
82	Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis. Journal of Breast Cancer, 2018, 21, 433.	1.9	19
83	<i>PIK3CA</i> Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. Journal of Breast Cancer, 2018, 21, 382.	1.9	14
84	Prognostic value of immunohistochemically detected p53 in adjuvant chemotherapyâ€treated triple negative breast cancer. Kaohsiung Journal of Medical Sciences, 2018, 34, 663-672.	1.9	8
85	Only estrogen receptor "positive―is not enough to predict the prognosis of breast cancer. Breast Cancer Research and Treatment, 2018, 172, 627-636.	2.5	10
86	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. Breast Cancer Research and Treatment, 2018, 171, 737-745.	2.5	27
87	Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment. Journal of Breast Cancer, 2018, 21, 182.	1.9	2
88	Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study. Breast Cancer Research and Treatment, 2018, 172, 273-282.	2.5	3
89	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. Journal of Breast Cancer, 2018, 21, 206.	1.9	8
90	The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. PLoS ONE, 2018, 13, e0197523.	2.5	5

#	Article	IF	CITATIONS
91	Berberine Suppresses Fibronectin Expression through Inhibition of c-Jun Phosphorylation in Breast Cancer Cells. Journal of Breast Cancer, 2018, 21, 21.	1.9	19
92	Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy. Journal of Breast Cancer, 2018, 21, 91.	1.9	10
93	Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 172, 437-444.	2.5	22
94	Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer. Journal of Breast Cancer, 2018, 21, 173.	1.9	28
95	Verification of a Western Nomogram for Predicting Oncotype DXâ,,¢ Recurrence Scores in Korean Patients with Breast Cancer. Journal of Breast Cancer, 2018, 21, 222.	1.9	4
96	Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells. Phytomedicine, 2018, 50, 43-49.	5.3	56
97	Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype. Oncology, 2018, 95, 163-169.	1.9	31
98	Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls. Palliative and Supportive Care, 2018, 16, 137-145.	1.0	19
99	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study Journal of Clinical Oncology, 2018, 36, 502-502.	1.6	14
100	Use of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytology proven axillary node-positive breast cancer at diagnosis Journal of Clinical Oncology, 2018, 36, e12640-e12640.	1.6	0
101	Who are happy survivors? Physical, psychosocial, and spiritual factors associated with happiness of breast cancer survivors during the transition from cancer patient to survivor. Psycho-Oncology, 2017, 26, 1922-1928.	2.3	27
102	A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2â ⁻² early breast cancer. Scientific Reports, 2017, 7, 45554.	3.3	26
103	MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer. Breast Cancer Research and Treatment, 2017, 164, 41-56.	2.5	51
104	Predictive Factors for Nonsentinel Lymph Node Metastasis in Patients With Positive Sentinel Lymph Nodes After Neoadjuvant Chemotherapy: Nomogram for Predicting Nonsentinel Lymph Node Metastasis. Clinical Breast Cancer, 2017, 17, 550-558.	2.4	18
105	Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society. Medical Oncology, 2017, 34, 118.	2.5	8
106	Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from â€~unknown significance' to â€~Likely pathogenic' based on clinical evidence in Korea. Breast, 2017, 33, 109-116.	2.2	16
107	Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?. Breast Cancer Research and Treatment, 2017, 161, 443-452.	2.5	145
108	Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Research and Treatment, 2017, 166, 833-842.	2.5	20

#	Article	IF	CITATIONS
109	Breast Cancer Screening With Mammography Plus Ultrasonography or Magnetic Resonance Imaging in Women 50 Years or Younger at Diagnosis and Treated With Breast Conservation Therapy. JAMA Oncology, 2017, 3, 1495.	7.1	112
110	Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case–Control Study. Clinical Breast Cancer, 2017, 17, 204-210.	2.4	24
111	Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2017, 161, 95-102.	2.5	28
112	Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer. Clinical Breast Cancer, 2017, 17, e19-e29.	2.4	14
113	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 329-336.	1.1	12
114	Development of a Nomogram to Predict N2 or N3 Stage in T1â€"2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy. Journal of Breast Cancer, 2017, 20, 270.	1.9	12
115	Basic Facts of Breast Cancer in Korea in 2014: The 10-Year Overall Survival Progress. Journal of Breast Cancer, 2017, 20, 1.	1.9	98
116	Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry. Journal of Breast Cancer, 2017, 20, 297.	1.9	31
117	Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. BMC Cancer, 2017, 17, 821.	2.6	5
118	Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. Journal of Pathology and Translational Medicine, 2017, 51, 69-78.	1.1	21
119	Fertility Rates in Young Korean Breast Cancer Patients Treated with Gonadotropin-Releasing Hormone and Chemotherapy. Journal of Breast Cancer, 2017, 20, 91.	1.9	6
120	Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study. Journal of Breast Cancer, 2017, 20, 74.	1.9	15
121	Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. Oncotarget, 2017, 8, 61538-61550.	1.8	28
122	A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012) Journal of Clinical Oncology, 2017, 35, 517-517.	1.6	1
123	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction. Oncotarget, 2017, 8, 50570-50581.	1.8	33
124	Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. Oncotarget, 2017, 8, 86423-86434.	1.8	14
125	Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget, 2017, 8, 100296-100311.	1.8	25
126	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. Journal of Breast Cancer, 2016, 19, 169.	1.9	11

#	Article	IF	CITATIONS
127	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. Cancer Research and Treatment, 2016, 48, 1338-1350.	3.0	56
128	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. Cancer Research and Treatment, 2016, 48, 1382-1388.	3.0	10
129	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. PLoS ONE, 2016, 11, e0163254.	2.5	6
130	Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer. PLoS ONE, 2016, 11, e0165814.	2.5	7
131	The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress. BMC Cancer, 2016, 16, 319.	2.6	19
132	Frequency of <scp>MED</scp> 12 mutations in phyllodes tumors: Inverse correlation with histologic grade. Genes Chromosomes and Cancer, 2016, 55, 495-504.	2.8	24
133	STC-1 expression is upregulated through an Akt/NF-κB-dependent pathway in triple-negative breast cancer cells. Oncology Reports, 2016, 36, 1717-1722.	2.6	14
134	The relationship between nuclear factor (NF)-lºB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Scientific Reports, 2016, 6, 31804.	3.3	44
135	Feasibility of Nippleâ€6paring Mastectomy with Immediate Breast Reconstruction in Breast Cancer Patients with Tumorâ€Nipple Distance Less Than 2.0Âcm. World Journal of Surgery, 2016, 40, 2028-2035.	1.6	21
136	MEK activity controls IL-8 expression in tamoxifen-resistant MCF-7 breast cancer cells. Oncology Reports, 2016, 35, 2398-2404.	2.6	7
137	Comparative analysis of BRCA1 and BRCA2 variants of uncertain significance in patients with breast cancer: a multifactorial probability-based model versus ACMG standards and guidelines for interpreting sequence variants. Genetics in Medicine, 2016, 18, 1250-1257.	2.4	16
138	Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society. Breast Cancer Research and Treatment, 2016, 159, 489-498.	2.5	6
139	Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype. Breast, 2016, 30, 111-117.	2.2	4
140	Elevated IL- $1\hat{l}^2$ expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone. Chemico-Biological Interactions, 2016, 258, 126-133.	4.0	38
141	Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. Breast Cancer Research and Treatment, 2016, 160, 475-489.	2.5	33
142	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer, 2016, 16, 138.	2.6	39
143	Limited Supraclavicular Radiation Field in Breast Cancer WithÂ≥ 10 Positive Axillary Lymph Nodes. Clinical Breast Cancer, 2016, 16, e15-e21.	2.4	1
144	Silibinin inhibits triple negative breast cancer cell motility by suppressing TGF- \hat{l}^2 2 expression. Tumor Biology, 2016, 37, 11397-11407.	1.8	28

#	Article	IF	Citations
145	MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells. Tumor Biology, 2016, 37, 4991-4999.	1.8	30
146	Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-Î ² 1 signaling pathway. Oncotarget, 2016, 7, 1544-1558.	1.8	43
147	Analysis of <i>BRIP1</i> Variants among Korean Patients with <i>BRCA1/2</i> Mutation-Negative High-Risk Breast Cancer. Cancer Research and Treatment, 2016, 48, 955-961.	3.0	8
148	Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study Journal of Clinical Oncology, 2016, 34, 195-195.	1.6	0
149	Patientâ€reported assessment of selfâ€management strategies of health in cancer patients: development and validation of the Smart Management Strategy for Health Assessment Tool (SAT). Psycho-Oncology, 2015, 24, 1723-1730.	2.3	24
150	Survival Improvement in Korean Breast Cancer Patients Due to Increases in Early-Stage Cancers and Hormone Receptor Positive/HER2 Negative Subtypes: A Nationwide Registry-Based Study. Journal of Breast Cancer, 2015, 18, 8.	1.9	12
151	Comparison of Clinicopathological Features and Treatment Results between Invasive Lobular Carcinoma and Ductal Carcinoma of the Breast. Journal of Breast Cancer, 2015, 18, 285.	1.9	12
152	The Basic Facts of Korean Breast Cancer in 2012: Results from a Nationwide Survey and Breast Cancer Registry Database. Journal of Breast Cancer, 2015, 18, 103.	1.9	39
153	Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis. Journal of Breast Cancer, 2015, 18, 22.	1.9	23
154	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. Journal of Breast Cancer, 2015, 18, 50.	1.9	5
155	Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery. Journal of Breast Cancer, 2015, 18, 386.	1.9	13
156	Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype. Korean Journal of Radiology, 2015, 16, 986.	3.4	17
157	Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLoS ONE, 2015, 10, e0124658.	2.5	27
158	Initial Experience with a Wireless Ultrasound-Guided Vacuum-Assisted Breast Biopsy Device. PLoS ONE, 2015, 10, e0144046.	2.5	11
159	Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. Oncotarget, 2015, 6, 24499-24510.	1.8	7
160	Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Oncology Reports, 2015, 34, 1613-1619.	2.6	21
161	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. Breast, 2015, 24, 213-217.	2.2	23
162	Lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma, is it really necessary? A randomized, controlled study. Surgery, 2015, 157, 518-525.	1.9	17

#	Article	IF	CITATIONS
163	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. Clinical Breast Cancer, 2015, 15, 512-518.	2.4	9
164	Elevated TGF- $\hat{1}^21$ and $-\hat{1}^22$ expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells. Cytokine, 2015, 75, 151-158.	3.2	40
165	Surgery of primary tumour has survival benefit in metastatic breast cancer with singleâ€organ metastasis, especially bone. ANZ Journal of Surgery, 2015, 85, 240-244.	0.7	23
166	Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer, 2015, 15, 138.	2.6	119
167	The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women. Annals of Surgical Oncology, 2015, 22, 3481-3488.	1.5	20
168	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. Clinical Breast Cancer, 2015, 15, e197-e204.	2.4	6
169	Incidental Findings on Simulation CT Images for Adjuvant Radiotherapy in Breast Cancer Patients. Technology in Cancer Research and Treatment, 2015, 14, 525-529.	1.9	6
170	Scanxiety and quality of life among breast cancer survivors Journal of Clinical Oncology, 2015, 33, e20569-e20569.	1.6	3
171	Comparison of prognosis and specific features according to tumor size in small-sized breast cancer with extensive lymph node involvement Journal of Clinical Oncology, 2015, 33, 81-81.	1.6	3
172	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget, 2015, 6, 43731-43742.	1.8	63
173	Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. Cancer Research and Treatment, 2015, 47, 765-773.	3.0	4
174	Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells. Annals of Surgical Treatment and Research, 2014, 87, 167.	1.0	18
175	Polyostotic Fibrous Dysplasia Mimicking Multiple Bone Metastases in a Patient with Ductal Carcinomaln Situ. Journal of Breast Cancer, 2014, 17, 83.	1.9	5
176	Breast Cancer Screening Knowledge and Perceived Health Beliefs among Immigrant Women in Korea. Journal of Breast Cancer, 2014, 17, 279.	1.9	13
177	Clinical Significance of the Axillary Arch in Sentinel Lymph Node Biopsy. Journal of Breast Cancer, 2014, 17, 244.	1.9	5
178	The Protective Effect of Parity in Hormone Receptorâ€Positive, Kiâ€67 Expressing Breast Cancer. World Journal of Surgery, 2014, 38, 1065-1069.	1.6	4
179	Invasive Paget disease of the breast: 20 years of experience at a single institution. Human Pathology, 2014, 45, 2480-2487.	2.0	22
180	Excision alone for small size ductal carcinoma in situ of the breast. Breast, 2014, 23, 586-590.	2.2	10

#	Article	IF	CITATIONS
181	Ovarian function preservation with GnRH agonist in young breast cancer patients: Does it impede the effect of adjuvant chemotherapy?. Breast, 2014, 23, 670-675.	2.2	12
182	Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population. Cancer Genetics, 2014, 207, 160-163.	0.4	8
183	Protein kinase C-α downregulates estrogen receptor-α by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells. Oncology Reports, 2014, 31, 1423-1428.	2.6	8
184	Role of secreted type I collagen derived from stromal cells in two breast cancer cell lines. Oncology Letters, 2014, 8, 507-512.	1.8	32
185	Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells. Oncology Reports, 2014, 32, 2230-2236.	2.6	27
186	Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells. Oncology Reports, 2014, 32, 2666-2672.	2.6	25
187	Primary Follicular Lymphoma in a Male Breast: A Case Report. Cancer Research and Treatment, 2014, 46, 104-107.	3.0	7
188	Comparison of the Characteristics of Medullary Breast Carcinoma and Invasive Ductal Carcinoma. Journal of Breast Cancer, 2013, 16, 417.	1.9	37
189	Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma <i>In Situ</i> . Journal of Breast Cancer, 2013, 16, 404.	1.9	27
190	Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiation Oncology Journal, 2013, 31, 222.	1.5	21
191	Surgical Outcomes of Bilateral Adrenalectomy. The Korean Journal of Endocrine Surgery, 2013, 13, 234.	0.1	0
192	Characteristics of medullary breast carcinoma compared with invasive ductal carcinoma Journal of Clinical Oncology, 2012, 30, 20-20.	1.6	0
193	Development of microRNA-145 for therapeutic application in breast cancer. Journal of Controlled Release, 2011, 155, 427-434.	9.9	109
194	The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging. Journal of Surgical Oncology, 2010, 102, 392-397.	1.7	44
195	One-step Nucleic Acid Amplification (OSNA): Intraoperative Rapid Molecular Diagnostic Method for the Detection of Sentinel Lymph Node Metastases in Breast Cancer Patients in Korean Cohort. Journal of Breast Cancer, 2010, 13, 366.	1.9	3
196	Biopsychosocial Predictors of the Quality of Life in Breast Cancer Patients. Journal of Breast Cancer, 2010, 13, 219.	1.9	11
197	Commentary on "The Number of Removed Lymph Nodes for an Acceptable False Negative Rate in Sentinel Node Biopsy for Breast Cancer". Journal of Breast Cancer, 2009, 12, 227.	1.9	0
198	A Comparison of Clinical Outcomes for Breast-conserving Treatment and Mastectomy for Early Breast Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2008, 26, 10.	0.1	2

#	Article	IF	CITATIONS
199	Clinical Analysis of Adrenal Tumors. The Korean Journal of Endocrine Surgery, 2003, 3, 147.	0.1	0
200	The Role of Needle Localization Breast Biopsy for the Diagnosis of Nonpalpable Breast Cancer. Journal of Korean Breast Cancer Society, 2000, 3, 42.	0.1	0
201	A Case of Sliding Hiatal Hernia associated with Bochdalek Hernia Repair. Journal of the Korean Association of Pediatric Surgeons, 1996, 2, 129.	0.1	O